Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 11 | 2024 | 45 | 1.270 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2020 | 2 | 0.810 |
Why?
|
| Fever | 2 | 2020 | 7 | 0.740 |
Why?
|
| Headache | 1 | 2020 | 3 | 0.700 |
Why?
|
| Carbapenems | 1 | 2020 | 1 | 0.680 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2023 | 9 | 0.610 |
Why?
|
| Staphylococcal Infections | 4 | 2023 | 13 | 0.610 |
Why?
|
| Humans | 23 | 2024 | 4931 | 0.570 |
Why?
|
| Nevirapine | 1 | 2017 | 2 | 0.540 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 4 | 0.540 |
Why?
|
| Anti-Retroviral Agents | 1 | 2017 | 5 | 0.540 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2017 | 9 | 0.540 |
Why?
|
| HIV Infections | 1 | 2017 | 167 | 0.460 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2024 | 4 | 0.430 |
Why?
|
| Neonatal Sepsis | 2 | 2024 | 2 | 0.380 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 40 | 0.370 |
Why?
|
| Male | 11 | 2024 | 2620 | 0.370 |
Why?
|
| Female | 13 | 2024 | 2964 | 0.360 |
Why?
|
| Vancomycin | 2 | 2021 | 4 | 0.350 |
Why?
|
| Adult | 9 | 2024 | 1402 | 0.310 |
Why?
|
| Cross Infection | 3 | 2024 | 10 | 0.300 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2021 | 10 | 0.280 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2016 | 4 | 0.280 |
Why?
|
| Infant, Newborn | 4 | 2024 | 121 | 0.270 |
Why?
|
| Acinetobacter Infections | 3 | 2018 | 5 | 0.260 |
Why?
|
| Acinetobacter baumannii | 3 | 2018 | 5 | 0.260 |
Why?
|
| Coccidioidomycosis | 2 | 2017 | 2 | 0.240 |
Why?
|
| Bacteremia | 3 | 2019 | 6 | 0.230 |
Why?
|
| Antimicrobial Stewardship | 1 | 2024 | 1 | 0.220 |
Why?
|
| Quality Improvement | 1 | 2024 | 27 | 0.210 |
Why?
|
| Chlorhexidine | 2 | 2023 | 2 | 0.210 |
Why?
|
| Mupirocin | 2 | 2023 | 2 | 0.210 |
Why?
|
| Blood Culture | 1 | 2023 | 1 | 0.210 |
Why?
|
| Pregnancy | 3 | 2023 | 417 | 0.200 |
Why?
|
| Influenza, Human | 1 | 2023 | 12 | 0.200 |
Why?
|
| Child | 2 | 2020 | 336 | 0.190 |
Why?
|
| Young Adult | 6 | 2024 | 382 | 0.190 |
Why?
|
| Middle Aged | 7 | 2024 | 1544 | 0.170 |
Why?
|
| Fomites | 1 | 2020 | 1 | 0.170 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 26 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 31 | 0.170 |
Why?
|
| Disinfection | 1 | 2019 | 1 | 0.160 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 3 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 58 | 0.160 |
Why?
|
| Decision Trees | 1 | 2019 | 5 | 0.160 |
Why?
|
| Fungal Proteins | 1 | 2018 | 2 | 0.150 |
Why?
|
| Virus Shedding | 1 | 2018 | 1 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2018 | 2 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 6 | 0.150 |
Why?
|
| Meningitis, Fungal | 1 | 2017 | 1 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 5 | 0.140 |
Why?
|
| HIV | 1 | 2017 | 5 | 0.140 |
Why?
|
| False Positive Reactions | 1 | 2017 | 9 | 0.140 |
Why?
|
| Viral Load | 1 | 2017 | 11 | 0.140 |
Why?
|
| Enterobacteriaceae | 1 | 2016 | 2 | 0.130 |
Why?
|
| Cryptococcus gattii | 1 | 2016 | 1 | 0.130 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2016 | 2 | 0.130 |
Why?
|
| Listeriosis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Coinfection | 1 | 2016 | 3 | 0.130 |
Why?
|
| Bayes Theorem | 3 | 2021 | 21 | 0.120 |
Why?
|
| Molecular Epidemiology | 1 | 2015 | 3 | 0.120 |
Why?
|
| Aged | 5 | 2019 | 1188 | 0.120 |
Why?
|
| Cat-Scratch Disease | 1 | 2015 | 1 | 0.120 |
Why?
|
| Bartonella henselae | 1 | 2015 | 1 | 0.120 |
Why?
|
| Lymphatic Diseases | 1 | 2015 | 3 | 0.120 |
Why?
|
| California | 3 | 2023 | 161 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 407 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 179 | 0.100 |
Why?
|
| Risk Factors | 3 | 2024 | 593 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2012 | 2 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2012 | 38 | 0.090 |
Why?
|
| beta-Lactams | 1 | 2011 | 1 | 0.090 |
Why?
|
| Daptomycin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 149 | 0.090 |
Why?
|
| Carrier State | 2 | 2023 | 2 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2021 | 14 | 0.090 |
Why?
|
| Vaccination | 2 | 2023 | 34 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2015 | 402 | 0.080 |
Why?
|
| Hospitals | 2 | 2023 | 14 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2015 | 445 | 0.080 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2008 | 1 | 0.080 |
Why?
|
| Pelvic Neoplasms | 1 | 2008 | 2 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 43 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 358 | 0.070 |
Why?
|
| Nursing Homes | 2 | 2018 | 7 | 0.070 |
Why?
|
| Antibodies, Bacterial | 2 | 2018 | 5 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 34 | 0.060 |
Why?
|
| Prevalence | 2 | 2016 | 184 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 6 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 6 | 0.060 |
Why?
|
| Personal Protective Equipment | 1 | 2024 | 3 | 0.060 |
Why?
|
| Health Personnel | 1 | 2024 | 40 | 0.060 |
Why?
|
| Sepsis | 1 | 2024 | 5 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 202 | 0.050 |
Why?
|
| Mice | 2 | 2018 | 555 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2023 | 3 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 6 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2023 | 19 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 53 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 98 | 0.050 |
Why?
|
| Animals | 2 | 2018 | 1369 | 0.050 |
Why?
|
| Hygiene | 1 | 2019 | 2 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 5 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 4 | 0.040 |
Why?
|
| Infection Control | 1 | 2019 | 7 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 24 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 49 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 123 | 0.040 |
Why?
|
| Acinetobacter | 1 | 2018 | 1 | 0.040 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2018 | 2 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2018 | 2 | 0.040 |
Why?
|
| Candida albicans | 1 | 2018 | 6 | 0.040 |
Why?
|
| Bacteria | 1 | 2018 | 8 | 0.040 |
Why?
|
| Biofilms | 1 | 2018 | 3 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 7 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 2 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2018 | 13 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2018 | 5 | 0.040 |
Why?
|
| Acute Disease | 1 | 2018 | 23 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2018 | 24 | 0.040 |
Why?
|
| Hospitalization | 1 | 2019 | 106 | 0.040 |
Why?
|
| Vasculitis | 1 | 2017 | 2 | 0.040 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2016 | 1 | 0.030 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2016 | 1 | 0.030 |
Why?
|
| beta-Lactamases | 1 | 2016 | 3 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2016 | 1 | 0.030 |
Why?
|
| Listeria monocytogenes | 1 | 2016 | 3 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 9 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 34 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2016 | 6 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 41 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 224 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2015 | 1 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 1 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 2015 | 2 | 0.030 |
Why?
|
| Multilocus Sequence Typing | 1 | 2015 | 2 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2015 | 2 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 18 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 14 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 160 | 0.030 |
Why?
|
| Adolescent | 1 | 2017 | 569 | 0.030 |
Why?
|
| Gentamicins | 1 | 2015 | 1 | 0.030 |
Why?
|
| Azithromycin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2015 | 7 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2017 | 513 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 45 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2015 | 2 | 0.030 |
Why?
|
| Oropharynx | 1 | 2015 | 2 | 0.030 |
Why?
|
| Skin Diseases, Infectious | 1 | 2015 | 2 | 0.030 |
Why?
|
| Los Angeles | 1 | 2015 | 244 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 152 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2013 | 70 | 0.030 |
Why?
|
| Colistin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Bacterial Load | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2012 | 5 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2012 | 5 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 85 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2011 | 12 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2011 | 35 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 10 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2008 | 4 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 33 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2008 | 162 | 0.020 |
Why?
|